Abstract: The present invention provides compositions and methods for the treatment or prevention of a neurological disease or disorder of the central nervous system (e.g., a storage disorder, lysosomal storage disorder, neurodegenerative disease, etc.) by reconstitution of brain myeloid cell and microglia upon transplantation of hematopoietic cells enriched in microglia reconstitution potential. The invention also provides compositions and methods for ablating and reconstituting microglia.
Type:
Grant
Filed:
October 16, 2017
Date of Patent:
April 16, 2024
Assignees:
CHILDREN'S MEDICAL CENTER CORPORATION, OSPEDALE SAN RAFFAELE S.R.L., POLITECNICO DI MILANO, FONDAZIONE TELETHON ETS, DANA-FARBER CANCER INSTITUTE, INC
Abstract: Provided herein are nanoparticles which enhance the immunogenicity of antigens for use in Beta coronavirus (e.g., MERS-CoV, SARS-CoV-1, or SARS-CoV-2) vaccines, as well as immunogenic compositions comprising the antigen nanoparticles and additional adjuvants for further enhancing immunogenicity.
Type:
Application
Filed:
June 23, 2022
Publication date:
April 11, 2024
Applicants:
Children's Medical Center Corporation, Dana-Farber Cancer Institute, Inc.
Inventors:
Francesco Borriello, Ofer Levy, David J. Dowling, Sirano Dhe-Paganon, Hyuk-Soo Seo
Abstract: The present invention relates to methods, compositions and kits for treatment of ribosomal disorders and ribosomopathies, e.g. Diamond Blackfan anemia (DBA). In some embodiments, the invention relates to the use of novel classes of compounds, i.e. inhibitors of RSK (p90S6K); inhibitors of p70S6K; and inhibitors of rps6, to treat ribosomal disorders and ribosomopathies. In some embodiments, the invention relates to the use of specific Chk2 inhibitors and to the use of specific phenothiazine derivatives to treat ribosomal disorders and ribosomopathies, e.g. DBA.
Type:
Grant
Filed:
February 12, 2021
Date of Patent:
April 2, 2024
Assignees:
THE CHILDREN'S MEDICAL CENTER CORPORATION, DANA-FARBER CANCER INSTITUTE, INC.
Inventors:
James Bradner, Jun Qi, Dennis Buckley, Leonard I. Zon, Elizabeth Macari
Abstract: Disclosed herein is a formulation that can take the form of an emulsion which contains total enteral or parenteral nutrition for a recipient subject. The formulation includes as the sole fat components: (i) medium chain triglycerides; and (ii) very long chain fatty acids selected from (a) very long chain omega-3 polyunsaturated fatty acids; and (b) docosahexaenoic acid and arachidonic acid in a ratio of about 10:1 (v/v or w/w) to about 2000:1 (v/v or w/w). The sole fat components provide about 10% to about 90% total calories of the formulation, and the medium chain triglycerides provide about 25%-95% total fat calories of the formulation. Methods and kits for utilizing the formulation and for treating various disorders and diseases that involve an inflammatory response are also disclosed.
Type:
Grant
Filed:
September 10, 2015
Date of Patent:
June 25, 2019
Assignees:
Children's Medical Center Corporation, Inc., Beth Israel Deaconess Medical Center, Inc.
Abstract: The present invention relates to methods of inhibiting angiogenesis associated with a disease or disorder with peptides homolgous to amino acid residues 130-137 or 132-139 of human troponin subunit I.
Type:
Application
Filed:
October 20, 2008
Publication date:
June 18, 2009
Applicants:
CHILDREN'S MEDICAL CENTER CORPORATION, INC., ALSERES PHARMACEUTICALS, INC.
Inventors:
Richard M. Thorn, Marc E. Lanser, Marsha A. Moses, Dmitri G. Wiederschain
Abstract: Disclosed herein is a method for treating and/or preventing peripheral nerve damage in a subject comprising administering to the subject a therapeutically effective amount of oncomodulin. Preferably, the subject is a mammal, most preferably, a human. In preferred embodiments, the oncomodulin may be used in combination with mannose, a mannose derivative and/or inosine.
Type:
Application
Filed:
May 14, 2007
Publication date:
June 18, 2009
Applicant:
CHILDREN'S MEDICAL CENTER CORPORATION, INC.
Abstract: A method for identifying agents useful for protection of a human neuron from injury. The method includes the steps of providing a cell which has NMDA receptor; selecting an agent potentially useful for oxidation of the NMDA receptor; treating the cell with the agent; and determining whether the NMDA receptor is oxidized by the agent.
Type:
Application
Filed:
January 8, 2003
Publication date:
May 29, 2003
Applicant:
The Children's Medical Center Corporation, Inc., a Massachusetts corporation